ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. It operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is based in Keego Harbor, Michigan.
IPO Year:
Exchange: NASDAQ
Website: zivobioscience.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2021 | $9.00 | Buy | Maxim Group |
ZIVOLife to be Granted Exclusive Worldwide Limited License to ZIVO Bioscience Intellectual Property for the Production and Supply of Whole Biomass Algal Products Conference call to be held in early November Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company's corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generating revenue from the Company's prop
Maxim Group initiated coverage of Zivo Bioscience with a rating of Buy and set a new price target of $9.00
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
3 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
8-K/A - Zivo Bioscience, Inc. (0001101026) (Filer)
8-K - Zivo Bioscience, Inc. (0001101026) (Filer)
10-Q - Zivo Bioscience, Inc. (0001101026) (Filer)
ARS - Zivo Bioscience, Inc. (0001101026) (Filer)
ZIVO Bioscience, Inc. (OTCQB:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, reports favorable results from its latest 42-day study with its product targeting coccidiosis in broiler chickens. The study, which was conducted in collaboration with a major global animal health company and replicated real-world poultry production environments, further validates the efficacy of ZIVO's non-antibiotic, immune-modulating product designed for the treatment of coccidiosis. Funded by the major animal health company, the study focused on the overall health and productivity of birds
ZIVO Bioscience, Inc. (NASDAQ:ZIVO), a pioneering biotech/agtech R&D company dedicated to developing therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day confirmatory study targeting coccidiosis in collaboration with a major global animal health company. This new study aims to further validate the efficacy of ZIVO's non-antibiotic, immune-modulating product designed for the prevention and treatment of coccidiosis in broiler chickens. Building upon the positive outcomes of previous trials, this study replicates real-world conditions to ensure the product's effectiveness in commercial poultry production envir
Reduction in intestinal damage enables poultry farms to optimize feed utilization Zivo Bioscience, Inc. (OTCQB:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces additional findings from its 42-day coccidiosis challenge study that demonstrate the product's positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO's product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use o
Zivo Bioscience, Inc. (OTCQB:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market (OTCQB), effective as of the opening of trading on Friday, January 26, 2024. Following this uplisting, ZIVO Bioscience continues to trade under the ticker symbol "ZIVO" and warrants continue to trade under the ticker symbol "ZIVOW". "In line with our strategic objectives, we have successfully completed the transition of our shares to the OTCQB market. This move
Zivo Bioscience, Inc. (OTC:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO's product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnershi
Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO is developing a product candidate for use in poultry feed that is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antimicrobial compounds. The 42-day study is intended to confirm the previously-reported positive effects of ZI
Zivo Bioscience, Inc. (NASDAQ:ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the "Reverse Stock Split") of its shares of common stock, par value $0.001 (the "Common Stock") effective at 5:00 p.m. ET on October 26, 2023 (the "Effective Time"). The Company's Common Stock will begin trading on a split-adjusted basis on October 27, 2023 and will continue to trade on the Nasdaq Capital Market under the existing symbol "ZIVO." The new CUSIP number for the Common Stock following the r
BLOOMFIELD HILLS, Mich, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that management will deliver a company presentation and will hold investor meetings at the 8th Annual Dawson James Small Cap Growth Conference being held Thursday, October 12, 2023 at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Fla. Event: 8th Annual Dawson James Small Cap Growth Conference Date: Thursday, October 12, 2023 Time: 9:00 a.m. Eastern Time Location: Wyndham Grand Jupiter at Harb
All test groups demonstrated statistically significant benefit in broiler health under simulated commercial conditions Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company's novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statisticall
ZWorldwide Commits to Minimum Annual Volume Purchases for Five Years ZIVO's Partner Alimenta Expects to Have Significantly Expanded Production Capacity Fully Operational in 2025 to Meet Projected Demand Zivo Bioscience, Inc. (NASDAQ:ZIVO) ("ZIVO" or the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today provided an update on the commercialization of Zivolife, its proprietary algal biomass as a food or food ingredient. Following strong initial sales, ZWorldwide, an independent distributor with exclusive rights to the Zivolife product in North America, informed ZI
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
SC 13D/A - Zivo Bioscience, Inc. (0001101026) (Subject)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
4 - Zivo Bioscience, Inc. (0001101026) (Issuer)
Maxim Group analyst Anthony Vendetti downgrades Zivo Bioscience (OTC:ZIVO) from Buy to Hold.
Gainers Safety Shot (NASDAQ:SHOT) stock increased by 21.5% to $2.77 during Thursday's regular session. Trading volume for Safety Shot's stock is 3.0 million as of 12:30 EST. This is 351.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $103.0 million. Oatly Group (NASDAQ:OTLY) stock moved upwards by 18.61% to $0.63. As of 12:30 EST, Oatly Group's stock is trading at a volume of 5.5 million, which is 143.1% of its average full-day volume over the last 100 days. The company's market cap stands at $373.0 million. Zivo Bioscience (NASDAQ:ZIVO) shares increased by 16.42% to $1.63. As of 12:30 EST, Zivo Bioscience's stock is trading at
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. ZIVO Bioscience The Trade: ZIVO Bioscience, Inc. (NASDAQ:ZIVO) 10% owner Strome Group Inc acquired a total of 366,286 shares
Zivo Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces the initiation of a 42-day study to further validate the efficacy of its novel immune-modulating treatment for coccidiosis in broiler chickens.ZIVO is developing a product candidate for use in poultry feed that is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antimicrobial compounds. The 42-day study is intended to confirm the previously-reported positive effects of ZIVO's
Zivo Bioscience, Inc. (NASDAQ:ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced that the Board of Directors of the Company approved a 1-for-6 reverse stock split (the "Reverse Stock Split") of its shares of common stock, par value $0.001 (the "Common Stock") effective at 5:00 p.m. ET on October 26, 2023 (the "Effective Time"). The Company's Common Stock will begin trading on a split-adjusted basis on October 27, 2023 and will continue to trade on the Nasdaq Capital Market under the existing symbol "ZIVO." The new CUSIP number for the Common Stock following the re
Gainers Splash Beverage Group (AMEX:SBEV) stock increased by 9.4% to $0.75 during Thursday's after-market session. At the close, Splash Beverage Group's trading volume reached 67.4K shares. This is 26.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $32.0 million. Bruush Oral Care (NASDAQ:BRSH) shares rose 5.09% to $1.03. The company's market cap stands at $1.6 million. Alkaline Water Co (NASDAQ:WTER) shares rose 4.96% to $0.28. The company's market cap stands at $2.9 million. Safety Shot (NASDAQ:SHOT) shares moved upwards by 4.62% to $1.13. The market value of their outstanding shares is at $36.6 million. Shineco (NASDAQ:SISI) shares r
Gainers Meiwu Technology Co (NASDAQ:WNW) stock moved upwards by 45.1% to $0.14 during Thursday's regular session. As of 13:31 EST, Meiwu Technology Co's stock is trading at a volume of 108.5 million, which is 23173.3% of its average full-day volume over the last 100 days. The company's market cap stands at $13.9 million. Better Choice Co (AMEX:BTTR) stock moved upwards by 24.93% to $0.2. Trading volume for Better Choice Co's stock is 53.7 million as of 13:31 EST. This is 5499.9% of its average full-day volume over the last 100 days. The company's market cap stands at $6.4 million. Planet Green Holdings (AMEX:PLAG) shares moved upwards by 12.69% to $0.74. Trading volume for this security a
Gainers Orchard Therapeutics plc (NASDAQ:ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS. Meiwu Technology Company Limited (NASDAQ:WNW) gained 69.4% to $0.1641. VS MEDIA Holdings Limited (NASDAQ:VSME) climbed 66% to $7.74. VS Media announced its expansion into Macau. SP Plus Corporation (NASDAQ:SP) shares gained 47.5% to $52.24 after Metropolis Technologies announced it will acquire the company for $1.5 billion. Camber Energy, Inc. (NYSE:CEI) jumped 40% to $0.3470. Better Choice Company Inc. (NYSE:BTTR) shares climbed 37.5% to $0.2198 after gaini
On Thursday, 369 companies hit new 52-week lows. Noteworthy Points From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was Coca-Cola (NYSE:KO). The smallest company by market cap to hit a new 52-week low was Neptune Wellness Solns (NASDAQ:NEPT). Aethlon Medical (NASDAQ:AEMD)'s stock fell the most, as it traded down 838.3% to reach a new 52-week low. American Tower (NYSE:AMT)'s stock showed potential to rebound, rebounding up 0.0% after reaching a new 52-week low. The following stocks achieved new 52-week lows on Thursday: Bank of America (NYSE:BAC) shares hit a yearly low of $25.56. The stock was down 0.73% on the session. Bristol-My